Issam A. Awad
University of Chicago
465 Papers
2.4K Citations
Issam A. Awad is an academic researcher from University of Chicago. The author has contributed to research in topics: Medicine & Intracerebral hemorrhage. The author has an hindex of 80, co-authored 380 publications. Previous affiliations of Issam A. Awad include Cleveland Clinic & University of Illinois at Chicago.
Chat about Author
Papers
Propranolol as therapy for cerebral cavernous malformations: a cautionary note
Robert Shenkar,Thomas R. Moore,Christian R Benavides,Rhonda Lightle,Matthew R Detter,Nicholas Hobson,Romuald Girard,Dorothy Debiasse,Mary Patrucco,Carol J. Gallione,Joseph M. Zabramski,Douglas A. Marchuk,Issam A. Awad +12 more
TL;DR: The recently published preclinical study showed that oral propranolol at 50 mg/kg/day, given at later ages, significantly decreased lesion burden in two murine models of CCM disease, but did not affect hemorrhage.
•Journal Article
LONG-TERM EXCESS MORTALITY IN 623 PATIENTS WITH BRAIN ARTERIOVENOUS MALFORMATIONS. Commentaries
Aki Laakso,Reza Dashti,Johanna Seppänen,Seppo Juvela,Kristjan Väärt,Mika Niemelä,Risto Sankila,Juha Hernesniemi,Issam A. Awad,Yasushi Takagi,Nobuo Hashimoto,Robert J. Dempsey,Robert A. Solomon,Andrew S. Little,Robert F. Spetzler,Ian F. Dunn,Robert M. Friedlander +16 more
TL;DR: AVMs are associated with long-term excess mortality that may be reduced by active, even partial, treatment and male patients have a higher excess mortality rate than female patients.
7
Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part I: Event Rates and Clinical Outcome
Kelly D. Flemming,Helen Kim,Stephanie F Hage,Jay Mandrekar,Serena Kinkade,Romuald Girard,Michel T. Torbey,Judy Huang,John Huston,Yunhong Shu,G. Lanzino,Reed G Selwyn,Blaine L. Hart,Marc C. Mabray,James Feghali,Haris I. Sair,Jared Narvid,Janine M. Lupo,Justine Lee,Agnieszka Stadnik,R. J. Alcazar-Felix,Robert Shenkar,Karen Lane,Nichol McBee,Kevin Treine,Noeleen Ostapkovich,Ying Wang,Richard E. Thompson,James I. Koenig,Timothy Carroll,Dan Hanley,Issam A. Awad +31 more
TL;DR: No score change was highly sensitive or specific for SH and could not be used as a primary end point in a trial, and functional outcomes and patient-reported outcomes generally improved over 2 years.
6